. 2023 Feb 3;28(3):1481. doi: 10.3390/molecules28031481

Table 3.

Cytotoxicity of compound 14b toward drug-resistant cancer cell lines ^a.

Cell Lines	IC₅₀, Mean ± SE (μM) ^b	Resistance Index ^c
A549	0.022 ± 0.002	1.59
A549/CDDP ^d	0.035 ± 0.021	1.59
C42B	0.051 ± 0.005	0.82
C42B/ENZR ^e	0.042 ± 0.011	0.82
MCF-7	0.027 ± 0.006	1.88
MCF-7/DOX ^f	0.051 ± 0.024	1.88
A2780	0.036 ± 0.004	1.17
A2780/TAX ^g	0.042 ± 0.011	1.17
HCT-8	0.089 ± 0.015	1.37
HCT-8/VCR ^h	0.122 ± 0.036	1.37

^a Cell lines were treated with different concentrations of the compounds for 48 h. Cell viability was measured by a CCK-8 assay, as described in the Materials and Methods section. ^b IC₅₀ values are indicated as the mean ± SE (standard error) of at least three independent experiments. ^c Resistance index = (IC₅₀ of drug-resistant cell lines)/(IC₅₀ of corresponding parent cancer cell lines); ^d A549/CDDP: A549 cell line resistant to cisplatin; ^e C42B/ENZR: C42b cell line resistant to Enzalutamide; ^f MCF-7/DOX: MCF-7 cell line resistant to doxorubicin; ^g A2780/TAX: A2780 cell line resistant to taxol; ^h HCT-8/VCR: HCT-8 cell line resistant to vincristine.